Mirabegron API

Name	Mirabegron
Chinese name	米拉贝隆
Cas Number	223673-61-8
Source	India
Qualifications	USDMF/-/-/-/-

The original research was Astellas Pharmaceuticals, which was approved for listing in Japan in September 2011. Mirabegron is the first β3-AR agonist used for the treatment of overactive bladder. It is a urinary incontinence treatment drug with a novel mechanism of action. It activates β3-adrenergic receptors on the detrusor muscle of the bladder to improve the bladder. The filling and storage capacity of urine. At present, the drugs for the treatment of overactive bladder are mainly selective M receptor antagonists. Although the curative effect is definite, these drugs are relatively selective and have some related side effects, such as uncontrolled glaucoma patients, severe Patients with urinary retention, a history of allergy to such drugs, and toxic megacolon are prohibited groups. Studies have shown that Mirabegron can effectively improve the main symptoms of frequent urination, urgency, and urinary incontinence, and it is safer than traditional M receptor antagonists.

Hot Tags: mirabegron api, China, suppliers, manufacturers, factory, customized, price, pricelist, in stock, Bemeprost API, Ticagrelor API, Bosentan API, Lifitegrast API, Deoxycholic Acid API, Aprepitant Aprepitant API

• Previous: Levosimendan API
• Next: Protein Iron Succinate API